乌干达东部HIV暴露未感染婴儿早期EB病毒感染相关临床与生物学因素
本研究基于ANRS 12174试验中201名乌干达HIV暴露未感染婴儿,于第50周检测抗VCA抗体,并在多个时间点检测干血斑EBV DNA以估计感染时间。结果显示43%婴儿第50周抗VCA IgG阳性,59名EBV DNA阳性婴儿中25%在26周内感染,12%在14周前感染。母婴EBV shedding与母亲血浆EBV DNA、HIV RNA检测及较低CD4计数相关,婴儿第50周EBV感染与母乳EBV shedding及母亲年轻相关,发生临床严重不良事件与婴儿较高EBV DNA水平相关。
要点
- 43%的HIV暴露未感染婴儿在第50周抗VCA IgG阳性。
- 25%的EBV DNA阳性婴儿在26周内感染,12%在14周前感染。
- 婴儿发生临床严重不良事件与较高EBV DNA水平相关。
核心结论
- HIV暴露未感染婴儿第一年内EBV感染由母亲HIV和EBV因素决定,且发生临床严重不良事件者EBV DNA水平更高。
研究设计与样本
- 基于ANRS 12174试验的201名乌干达HIV暴露未感染婴儿,第50周检测抗VCA抗体,并在1、6、14、26、38、50周干血斑检测EBV DNA以估计感染时间。
主要发现
- 59名EBV DNA阳性婴儿中25%在最初26周内感染,12%在14周前感染。
- 母乳EBV shedding与母亲血浆EBV DNA(P = .009)、HIV RNA检测(P = .039)及较低CD4计数(P = .001)相关,并与血浆EBV DNA水平相关(P = .002)。
- 婴儿第50周EBV感染与母乳EBV shedding(P = .009)及母亲年轻(P = .029)相关。
- 发生临床严重不良事件(包括疟疾和肺炎)与婴儿较高EBV DNA水平相关(P = .010)。
临床怎么用
- 对HIV暴露未感染婴儿应关注母亲EBV shedding和免疫状态,并监测婴儿EBV DNA水平以评估严重不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune control of Epstein-Barr virus (EBV) infection is impaired in individuals with HIV. We explored maternal factors associated with EBV acquisition in HIV-exposed uninfected (HEU) infants and the relationship between EBV infection and serious adverse events (SAEs) during the first year of life. METHODS: 201 HEU infants from Uganda enrolled in the ANRS 12174 trial were tested for antiviral capsid antigen (anti-VCA) antibodies at week 50. Date of infection was estimated by testing EBV DNA at weeks 1, 6, 14, 26, 38, and 50 postpartum on dried blood spots. RESULTS: Eighty-seven (43%) infants tested positive for anti-VCA IgG at week 50. Among the 59 infants positive for EBV DNA, 25% were infected within the first 26 weeks. Almost half (12%) were infected before week 14. Shedding of EBV in breast milk was associated with EBV DNA in maternal plasma (P = .009), HIV RNA detection (P = .039), and lower CD4 count (P = .001) and correlated with plasma EBV DNA levels (P = .002). EBV infant infection at week 50 was associated with shedding of EBV in breast milk (P = .009) and young maternal age (P = .029). Occurrence of a clinical SAE, including malaria and pneumonia, was associated with higher levels of EBV DNA in infants (P = .010). CONCLUSIONS: By assessing EBV infection in HEU infants we observed that infection during the first year is determined by HIV and EBV maternal factors and that EBV DNA levels were higher among infants with clinical SAEs. CLINICAL TRIALS REGISTRATION: NCT00640263.
引用
- Montoya-Ferrer A, Sanosyan A, Fayd'herbe de Maudave A, et al. Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda. Clin Infect Dis. 2021. PMID: 32067040. doi:10.1093/cid/ciaa161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。